Show simple item record

dc.contributor.authorLloyd, MG
dc.contributor.authorHuckvale, R
dc.contributor.authorCheung, K-MJ
dc.contributor.authorRodrigues, MJ
dc.contributor.authorCollie, GW
dc.contributor.authorPierrat, OA
dc.contributor.authorGatti Iou, M
dc.contributor.authorCarter, M
dc.contributor.authorDavis, OA
dc.contributor.authorMcAndrew, PC
dc.contributor.authorGunnell, E
dc.contributor.authorLe Bihan, Y-V
dc.contributor.authorTalbot, R
dc.contributor.authorHenley, AT
dc.contributor.authorJohnson, LD
dc.contributor.authorHayes, A
dc.contributor.authorBright, MD
dc.contributor.authorRaynaud, FI
dc.contributor.authorMeniconi, M
dc.contributor.authorBurke, R
dc.contributor.authorvan Montfort, RLM
dc.contributor.authorRossanese, OW
dc.contributor.authorBellenie, BR
dc.contributor.authorHoelder, S
dc.date.accessioned2022-02-10T12:06:22Z
dc.date.available2022-02-10T12:06:22Z
dc.date.issued2021-12-09
dc.identifier.citationJournal of medicinal chemistry, 2021, 64 (23), pp. 17079 - 17097
dc.identifier.issn0022-2623
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5005
dc.identifier.eissn1520-4804
dc.identifier.eissn1520-4804
dc.identifier.doi10.1021/acs.jmedchem.1c00946
dc.identifier.doi10.1021/acs.jmedchem.1c00946
dc.description.abstractWe describe the optimization of modestly active starting points to potent inhibitors of BCL6 by growing into a subpocket, which was occupied by a network of five stably bound water molecules. Identifying potent inhibitors required not only forming new interactions in the subpocket but also perturbing the water network in a productive, potency-increasing fashion while controlling the physicochemical properties. We achieved this goal in a sequential manner by systematically probing the pocket and the water network, ultimately achieving a 100-fold improvement of activity. The most potent compounds displaced three of the five initial water molecules and formed hydrogen bonds with the remaining two. Compound 25 showed a promising profile for a lead compound with submicromolar inhibition of BCL6 in cells and satisfactory pharmacokinetic (PK) properties. Our work highlights the importance of finding productive ways to perturb existing water networks when growing into solvent-filled protein pockets.
dc.formatPrint-Electronic
dc.format.extent17079 - 17097
dc.languageeng
dc.language.isoeng
dc.publisherAMER CHEMICAL SOC
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHumans
dc.subjectAntineoplastic Agents
dc.subjectCrystallography, X-Ray
dc.subjectStructure-Activity Relationship
dc.subjectDrug Design
dc.subjectHydrogen Bonding
dc.subjectSolubility
dc.subjectProto-Oncogene Proteins c-bcl-6
dc.titleInto Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket.
dc.typeJournal Article
dcterms.dateAccepted2021-11-30
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1021/acs.jmedchem.1c00946
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
dc.relation.isPartOfJournal of medicinal chemistry
pubs.issue23
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 4 (including Analytical Chemistry)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Evaluation and Molecular Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design
pubs.publication-statusPublished
pubs.volume64
pubs.embargo.termsNo embargo
icr.researchteamClinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
icr.researchteamMedicinal Chemistry 4 (including Analytical Chemistry)
icr.researchteamTarget Evaluation and Molecular Therapeutics
icr.researchteamHit Discovery & Structural Design
dc.contributor.icrauthorPierrat, Olivier
dc.contributor.icrauthorLe Bihan, Yann-Vai
dc.contributor.icrauthorTalbot, Rachel
dc.contributor.icrauthorRaynaud, Florence
dc.contributor.icrauthorBurke, Rosemary
dc.contributor.icrauthorVan Montfort, Robert
dc.contributor.icrauthorRossanese, Olivia
dc.contributor.icrauthorHoelder, Swen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/